MJ Hudson has advised 4BIO Partners LLP (4BIO) on the establishment of a closed-ended venture capital fund. 4BIO is a London-based investment firm that invests in venture capital and public equities in life sciences focussing on gene, cell and RNA-based therapies.
The fund focuses on investments in unlisted life sciences companies with a focus on development stage clinical life sciences, pre-clinical life sciences, early clinical life sciences, and advanced therapeutics. 4BIO is seeking to raise up to USD150 million of investor commitments.
MJ Hudson law division supported the 4BIO team right from the outset of the launch of their new fund proposition, providing legal and structural advice, as well as managing other service providers to first closing. In addition to the current mandate, MJ Hudson has provided advice and strategic support relating to the sub-advisory roles undertaken by the 4BIO team for other managers as well as potential launch of a listed life sciences fund.
The Venture Capital team at MJ Hudson Law was led by Partner Karma Samdup, with support from Ronan McCann, Jacob Freeman and Arooj Khan.
Commenting on the closing, Karma Samdup, lead Partner on the matter, says: “We are very pleased to have assisted the 4BIO Capital team with the launch of their new life-sciences fund. The success of the 4BIO Capital team to date with their fundraising demonstrates the demand in the market for investments in advanced therapies which address unmet medical and social needs. We look forward to continuing to support the 4BIO Capital team as they work towards achieving their target fund size.”
Kieran Mudryy, Partner at 4BIO, says: “We appreciated the support of the MJ Hudson team in assisting us with the launch of our latest advanced therapies fund. Their ability to navigate complex issues and provide creative, pragmatic solutions made a substantial difference and enabled us to achieve the first close of the fund faster. We look forward to continuing our partnership with the MJ Hudson team as we work towards meeting our target fund size, which will enable us to continue to invest in innovative biotech companies creating effective, reasonable and sustainable advanced therapies aimed at curing chronic disease.”
